Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Ended early

PICO-NGS First time ultra-sensitive and simultaneous quantification of proteins, interactions, and post-translational modifications in single cells to enable exponential growth in proteomics and interactomics

Coordinator
Actome GmbH, Germany
Runs
1 August 2023 to 31 July 2025
Status
Ended early
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190140802

What the project is doing

In the project's own words, from its summary on CORDIS.

In a human cell there are about 20k protein coding genes (genome) that originate ~100k proteins (proteome). Proteins are involved in complex networks of protein-protein interactions (PPIs) influenced by post-translational modifications (PTMs), the interactome of living cells (~800,000 entities). The genome is mostly static throughout cell lifetime and can be sequenced today in <1h. The proteome and interactome are changing with e.g., environment and health, and not yet fully known.

Today's methods for proteomics and interactomics are tedious, and lack sensitivity, quantitativity and parallelism. PICO-NGS combines ultra-high sensitivity (>10 fM) with high parallelism measuring proteins, PPIs, and PTMs simultaneously (>50 targets). This will disrupt the global proteomics market (€29 B worth, 16% CAGR). This will fertilise ground-breaking academic research and accelerate developments in e.g., Pharma (drug discovery), Biotech (biomarkers/diagnosis), and Agrotech (crop sciences) industries.

Topics

Who is involved

OrganisationCityCountryRole
Actome GmbHFreiburg im BreisgauGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI